Guggenheim 3rd Annual Healthcare Innovation Conference - AMYLYX PHARMACEUTICALS INC

Explicit Guidance:

• NDA Submission: Targeting submission of the New Drug Application (NDA) for Avexotide by the end of the current year (FY2024).
• Launch Timeline: Anticipated product launch in 2027, contingent on regulatory approval.
• Dosing Strategy: Commercial formulation planned as a single 90-milligram injection; this replaces the back-to-back 90-mg injections (totaling 180 mg? *Correction: Transcript says "90 back-to-back" which implies 2x 90mg? No, transcript says "back-to-back injection of 245-milligram doses... total 90 back-to-back" - Wait, reading transcript carefully: "back-to-back injection of 245-milligram doses... total 90 back-to-back" is likely a transcription error in the source text or a specific dosage logic. Let's re-read: "the dose was the same as was done in the phase 2B, which was a back-to-back injection of 245-milligram doses. So total 90 back-to-back, you know, two injections." This is internally contradictory in the transcript (245 vs 90). However, the commercial intent is explicitly stated as a single 90-milligram dose. The "245" appears to be a transcript error for "90" or a specific milligram split not clarified, but the commercial plan is clear: single 90mg injection.)
• Patient Population Target: Initial commercial target likely 120,000 US patients (if restricted to Post-Roux-en-Y gastric bypass) or 160,000 US patients (if expanded to all gastric surgeries).

Business-Segment Outlook:

• Product (Avexotide): Focus on the "Lucidity" Phase 3 data which met primary endpoints for reducing Level 2 and Level 3 hypoglycemia with high statistical significance (p-value 0.00003).
• Market Size: Estimating ~160,000 US patients with Post-Bariatric Hypoglycemia (PBH), representing a "large rare disease" with zero current FDA-approved therapies.
• Commercial Preparation: Full launch preparation mode involving disease education campaigns ("Uncover the Mystery of PBH"), payer preparation, and recruitment of a leadership team for medical affairs and commercial operations.
• Label Strategy: Preparing to argue that pathophysiology is consistent across all gastric surgeries (Roux-en-Y, Sleeve, Gastrectomy), though initial approval may be restricted to Roux-en-Y (approx. 120,000 patients) pending regulatory feedback.

Market and Competitive Outlook:

• Unmet Need: 90% of PBH patients describe themselves as disabled; currently no approved therapy exists, creating a "helplessness" among physicians that Amelix aims to resolve.
• Competitive Landscape: Identified as a first-in-class opportunity with no direct competitors for FDA-approved treatment.
• Physician Adoption: Anticipated high excitement among endocrinologists and patient advocates; "high intent to treat" across severity levels (ER visits vs. home events) due to the danger of neuroglycopenia.
• Awareness Strategy: Leveraging Obesity Week and "Total Office Calls" (engaging doctors, nurses, back-office staff) to build market depth, focusing on high-density patient sites while using digital tools for broader reach.

Macro / Industry Outlook:

• Regulatory Environment: Anticipated FDA approval pathway; noting that while ICD-10 coding for PBH is now available (beneficial for tracking/reimbursement), it is a tracking code, not a reimbursement requirement.
• Healthcare System Dynamics: Expecting the need for education to shift from "no treatment" to active management; recognizing that PBH requires specialized centers but the patient population is concentrated enough to support a dedicated commercial approach.
• Expanded Access Program (EAP): Launching an EAP to provide pre-approval access; operations driven by physician requests and local IRB/protocol setup rather than a central enrollment engine.

Strategic Initiatives:

• NDA Filing: Executing a year-end NDA submission based on "pre-planning" and risk-based work initiated prior to Phase 3 readout.
• Manufacturing: Scaling manufacturing capabilities to support the single 90-mg commercial dose (currently using this format for the Open Label Extension).
• Team Building: Established a world-class regulatory, clinical, and commercial leadership team with prior experience in NDAs/BLAs globally to accelerate execution.
• Clinical Extensions: >90% of Phase 3 participants completed the study and entered the Open Label Extension (OLE), providing further data generation and presentation opportunities.
• Launch Timing: Planning a ramp-up of disease education and payer negotiations leading into a 2027 launch.

Risks and Headwinds to Outlook:

• Regulatory Labeling: Potential for the FDA to restrict the initial indication to only PBH following Roux-en-Y gastric bypass (excluding Sleeve/Gastrectomy patients), necessitating additional clinical work to broaden the label.
• Market Education: Significant time and resource required to educate both patients and physicians on a previously unrecognized/untreated condition; "disease education" is a primary early-stage focus.
• Operational Complexity: Expanded Access Program (EAP) setup is not instantaneous; requires individual site protocols, IRB approvals, and budgeting, potentially slowing early access compared to a streamlined trial rollout.
• Timeline Execution: Dependence on maintaining momentum for a late-2024 NDA submission to hit a 2027 launch; any regulatory feedback delays could impact this window.

Management Tone on the Future:

• Confidence Level: High confidence ("incredible excitement," "world-class team," "very strong position") regarding the data consistency across trials and the team's ability to execute the NDA process efficiently.
• Differentiation vs. Peers: Explicitly stated that the company is an "absolute outlier" in the industry regarding speed of execution from Phase 3 data to NDA filing, attributing this to extensive pre-planning.
• Market Sentiment: Describes the market and physician reaction as "very encouraging" and "tremendous excitement," contrasting the current "helplessness" of physicians with the potential for Avexotide to "fundamentally change the practice of PBH."
• Hedges: While confident in the "totality of data," they acknowledge the regulatory uncertainty regarding the final label scope (Roux-en-Y only vs. all gastric surgeries).

Miscellaneous:

• Data Consistency: Strong emphasis on the consistency of data between Phase 2 and Phase 3 trials, and across different measurement methods (finger stick vs. continuous glucose monitoring) for both Level 2 and Level 3 endpoints.
• Safety Profile: No evidence of weight gain or other expected metabolic concerns in the 16-week data; safety profile described as consistent with prior trials.
• Event Schedule: Company presenting top-line data at Obesity Week (August) and hosting a dedicated investor event on a Sunday.